General Equity Holdings’s Cardlytics CDLX Stock Holding History

General Equity Holdings’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-53,347	Closed	-$1.71M	–	7
2024 Q3	$1.71M	Sell	53,347 -9,059	-15%	-$503K	1.19%	6
2024 Q2	$5.12M	Hold	62,406	–	–	3.13%	5
2024 Q1	$9.04M	Hold	62,406	–	–	7.51%	3
2023 Q4	$5.75M	Buy	62,406 +14,784	+31%	+$1.5M	6.65%	3
2023 Q3	$7.86M	Sell	47,622 -3,008	-6%	-$391K	9.59%	4
2023 Q2	$3.2M	Sell	50,630 -100,269	-66%	-$6.07M	4.74%	6
2023 Q1	$5.12M	Buy	150,899 +62,891	+71%	+$3.29M	12.06%	4
2022 Q4	$5.09M	Buy	88,008 +23,617	+37%	+$1.46M	12.54%	4
2022 Q3	$6.05M	Buy	+64,391	New	+$9.16M	9.43%	4
2019 Q4	–	Sell	-9,720	Closed	-$3.26M	–	13
2019 Q3	$3.26M	Buy	+9,720	New	+$3.12M	2.6%	11

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

General Equity Holdings's CDLX Position: Q4 2024 in Review

General Equity Holdings sold out of Cardlytics (CDLX) in Q4 2024, closing a stake of 53,347 shares — an estimated $1.71M sold.

General Equity Holdings first reported a position in CDLX in Q3 2019 and held it in 10 quarters. The position peaked at $9.04M in Q1 2024. 108 funds tracked by Wall St. Rank hold CDLX as of Q4 2024.

General Equity Holdings reported no remaining Cardlytics position as of Q4 2024 after selling out during the quarter.
General Equity Holdings sold 53,347 Cardlytics shares in Q4 2024, an estimated $1.71M.
General Equity Holdings first reported a position in Cardlytics in Q3 2019 and held it in 10 quarters.
General Equity Holdings's Cardlytics position peaked at $9.04M in Q1 2024.
108 funds tracked by Wall St. Rank held Cardlytics as of Q4 2024.

Based on General Equity Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.